|
Mecasermine Rinfabate Human Studies At least 129 human patients have taken Mecasermine Rinfabate while participating in controlled clinical trials.� Countless have used the product through GHIS prescription, off-label prescription, and investigational new drug (IND) compassionate use authorization. No Serious Adverse Events (SAE)'s have been attributed to the intervention. The peer reviewed reports of five of the five clinical trials are here. DocumentsDate addedSaukkonen, Shojaee-Moradie, Williams, Amin, Yuen, Watts, Acerini, Umpleby, Dunger. Diabetes, Aug. 2006 Camacho-Huebner, Rose. Journal of Endocrinology and Metabolism. 2006 Boonen, Rosen, Bouillon, Sommer. Journal of Endocrinology and Metabolism. 2002 Clemmons, Sleevi, Busby. Journal of Endocrinology and Metabolism. 2006 FDA full report for Mecasermine Rinfabate's marketing approval, trademarked as Iplex. Includes study results from GHIS trial.
|


